Annual Report 2025

Founded in 1990, the Group focuses on the research and development, production and sales of pharmaceuticals, and ranks among the leading integrated pharmaceutical companies in China. The Group witnessed its listing on the Main Board of the Hong Kong Stock Exchange on 15 June 2007 (Stock Code: 3933). At present, the Group stands as a constituent stock of the Hang Seng Composite Index series, and has achieved an MSCI ESG rating of AA, which is an industry leading performance. Over three decades of rapid development, the Group has established three core business segments covering intermediate products, bulk medicine and finished products, and continues to optimize its vertically integrated business model. The Group currently owns eleven production bases, covering intermediate products and bulk medicine, finished products, health & wellness products, animal healthcare products, empty capsule casings and medical devices. The Group continues to expand its international business footprint, with sales networks covering nearly 80 countries and regions worldwide. The Group continues to expand its innovative R&D and international perspective, establishing a multi- platform synergistic layout for comprehensive development. The Group focuses on fields including endocrinology, metabolism, autoimmunity, anti-infection and ophthalmology, with several Class 1 innovative drugs having entered the clinical trial stage. The Group is actively advancing new drug out-licensing and diversified business development, continuously building a global innovation network. To date, the Group has over 100 projects under development and has obtained over 120 patents. Keeping the corporate mission of “Making Life More Valuable” in mind, the Group will continue to deepen its innovative research and development and global layout, provide more quality and efficient products and services, and contribute to the high-quality development of China and the global pharmaceutical industry.